Actively Recruiting
Metabolic Characterization of Space Occupying Lesions of the Brain
Led by Insel Gruppe AG, University Hospital Bern · Updated on 2024-11-25
55
Participants Needed
1
Research Sites
226 weeks
Total Duration
On this page
Sponsors
I
Insel Gruppe AG, University Hospital Bern
Lead Sponsor
S
Swiss National Science Foundation
Collaborating Sponsor
AI-Summary
What this Trial Is About
High field MR-technologies are expected to boost metabolic spectroscopic imaging (MRSI), but also CEST-MRI. This is due to the fact that increased SNR is available which can be used to increase the spatial resolution of all sequences, or reduction of measurement times. Recent findings has shown that MRSI can be used to evaluate the isocitrate dehydrogenase (IDH) status of gliomas, a brain tumor type which is most often diagnosed in humans. Patients with IDH-mutated gliomas have a much longer survival time that IDH-wildtype. In IDH-mutated gliomas the substance 2-hydroxy-glutarate (2HG) is found, whereas in IDH-wildtype gliomas it is not. The underlying trial aims to measure 2HG directly with different MRSI sequences at 3 Tesla (3T) and 7 Tesla (7T) magnetic field strength. Apart from MRSI-techniques for IDH-typing it has been shown that CEST-imaging can also be performed to determine the IDH-status of gliomas. A total of 75 patients and 50 healthy controls will be examined in this study to evaluate the most accurate method for pre-operative IDH-status determination.
CONDITIONS
Official Title
Metabolic Characterization of Space Occupying Lesions of the Brain
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Healthy people who are able to lie in the MR scanner for one hour
- Patients with suspected mass in the brain
- Written informed consent
You will not qualify if you...
- Persons under the age of 18
- Persons who are mentally unable to choose to participate
- Pregnant women
- Patients with oncological findings or neurodegenerative findings in the past
- Wearing active implants (e.g. pacemakers and neurostimulators)
- Emergency patients
- Persons with tattoos on the head or neck area
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Institute for Diagnostic and Interventional Neuroradiology, University Hospital Bern
Bern, Switzerland, 3010
Actively Recruiting
Research Team
J
Johannes Slotboom, PhD
CONTACT
M
Marwan El-Koussy, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here